MEIP - MEI Pharma, Inc.
| Previous Close | 1.6900 |
| Open | 1.7000 |
| Bid | 1.6600 x 2900 |
| Ask | 1.6700 x 3000 |
| Day's Range | 1.6300 - 1.7000 |
| 52 Week Range | 1.4400 - 4.8000 |
| Volume | 134,155 |
| Avg. Volume | 476,943 |
| Market Cap | 117.629M |
| Beta (3Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9380 |
| Earnings Date | Aug 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.31 |
- PR Newswire
MEI Pharma to Release 2019 Fiscal Year End Financial Results and Provide Corporate Update on August 28, 2019
SAN DIEGO, Aug. 21, 2019 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2019 fiscal year end financial results after the close of the U.S. financial markets on August 28, 2019. Please join the conference call at least 10 minutes early to register.
- Simply Wall St.
What Did MEI Pharma, Inc.'s (NASDAQ:MEIP) CEO Take Home Last Year?
Dan Gold became the CEO of MEI Pharma, Inc. (NASDAQ:MEIP) in 2010. This report will, first, examine the CEO...
- Simply Wall St.
Imagine Owning MEI Pharma (NASDAQ:MEIP) While The Price Tanked 63%
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...
- PR Newswire
MEI Pharma Appoints Longtime Industry Consultant and Executive Tamar Howson to its Board of Directors
SAN DIEGO, July 3, 2019 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced the appointment of Tamar Howson, M.S., MBA, to its board of directors. "I am excited to join MEI with its promising pipeline of drug candidates and the tremendous opportunity to improve the lives of patients with cancer," said Tamar Howson. Ms. Howson is a highly experienced business development executive and consultant with more than 30 years of service in the pharmaceutical and biotechnology industries.
- Insider Monkey
Is MEI Pharma Inc (MEIP) A Good Stock To Buy?
You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund managers like Jeff Ubben, George Soros […]
- PR Newswire
MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)
-- 83% overall response rate in patients with relapsed or refractory follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma -- -- Intermittent dosing schedule demonstrates comparable ...
- PR Newswire
MEI Pharma Presents Updated Clinical Data from the ME-401 Monotherapy and in Combination with Rituximab Phase 1b study in Patients with Follicular Lymphoma at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
-- 80% overall response rate in patients with relapsed or refractory follicular lymphoma -- -- Intermittent dosing schedule demonstrates comparable overall response rates with lower rate of delayed Grade ...
- PR Newswire
MEI Pharma Presents Clinical Results for ME-344 in Combination with Bevacizumab in Early HER2 Negative Breast Cancer Patients at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO, June 1, 2019 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced data presented at ASCO 2019 from an investigator-initiated study of investigational ME-344 in combination with bevacizumab (marketed as Avastin®) in patients with early HER2-negative breast cancer. This study demonstrated proof of biologic anti-tumor activity as measured by a statistically significant reduction in Ki67, a measure of cell proliferation that is highly correlated with tumor response, in the group of patients treated with ME-344 compared to an increase in the group receiving saline. "Data from this clinical study of ME-344 in combination with bevacizumab represents a potential novel approach to disrupting tumor metabolism and limiting tumor proliferation by inhibiting the heightened energy production necessary for cell division and cancer growth," stated the study principal investigator, Miguel Quintela-Fandino, M.D., Ph.D., Director of the Clinical Research Program, Centro Nacional De Investigaciones Oncologicas, Madrid, Spain.
- PR Newswire
MEI Pharma to Present at the Jefferies 2019 Global Healthcare Conference
SAN DIEGO, May 31, 2019 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 1:00 p.m. ET. A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma's website at http://www.meipharma.com. An archived replay of the webcast will be available on MEI Pharma's website for at least 30 days after the live event concludes.
- PR Newswire
MEI Pharma to Present New Clinical Results on ME-401 and ME-344 Programs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
International Conference on Malignant Lymphoma (ICML) Selects ME-401 Abstract for Oral Presentation SAN DIEGO , May 15, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical ...
- PR Newswire
MEI Pharma Reports Third Quarter Fiscal Year 2019 Results and Operational Highlights
SAN DIEGO , May 9, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its third quarter ...
- Zacks
Earnings Preview: MEI Pharma (MEIP) Q3 Earnings Expected to Decline
MEI Pharma (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
How Does MEI Pharma, Inc. (NASDAQ:MEIP) Affect Your Portfolio Volatility?
If you're interested in MEI Pharma, Inc. (NASDAQ:MEIP), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. Volatility is considered to be...
- GuruFocus.com
2 Biotech Stock Picks From Legendary Investor Joseph Edelman
While famed value investors like Warren Buffett (Trades, Portfolio) and Seth Klarman (Trades, Portfolio) get most of the attention, there are plenty of other portfolio managers that have similar long-term track records. Joseph Edelman, the founder of Perceptive Advisors, is one such investor. Warning! GuruFocus has detected 2 Warning Signs with FOMX.
- PR Newswire
MEI Pharma to Present at the 18th Annual Needham Healthcare Conference
SAN DIEGO, April 2, 2019 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 10:40 a.m. ET. A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma's website at http://www.meipharma.com. An archived replay of the webcast will be available on MEI Pharma's website for at least 30 days after the live event concludes.
- PR Newswire
MEI Pharma to Present at the 29th Annual Oppenheimer Healthcare Conference
SAN DIEGO, March 12, 2019 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the 29th Oppenheimer Healthcare Conference on Tuesday, March 19, 2019 at 11:30 a.m. ET. A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma's website at http://www.meipharma.com. An archived replay of the webcast will be available on MEI Pharma's website for at least 30 days after the live event concludes.
- Simply Wall St.
A Holistic Look At MEI Pharma, Inc. (NASDAQ:MEIP)
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on MEI Pharma, Inc. (NASDAQ:MEIP) due to its excellent fundamentals in moreRead More...
- PR Newswire
MEI Pharma Reports Second Quarter Fiscal Year 2019 Results and Operational Highlights
-- MEI Remains in Strong Position as ME-401 Advances to Global Phase 2 Study to Support FDA Accelerated Approval -- SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage ...
- Zacks
MEI Pharma (MEIP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
MEI Pharma (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
What Percentage Of MEI Pharma, Inc. (NASDAQ:MEIP) Shares Do Insiders Own?
The big shareholder groups in MEI Pharma, Inc. (NASDAQ:MEIP) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a Read More...
- PR Newswire
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
The data demonstrate a 9% discontinuation rate due to adverse events, a substantially lower rate than observed in an earlier study, as well as an encouraging 36% complete response rate among patients receiving at least 6 cycles of treatment. The ongoing Phase 2 open-label study is evaluating a 45 mg dose of pracinostat in combination with azacitidine in order to improve safety/tolerability and retain patients in study longer than in an earlier Phase 2 study evaluating a 60 mg dose.
- PR Newswire
MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting
SAN DIEGO, Dec. 2, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that results from an ongoing Phase 1b study support the complementary potential of intermittent and continuous dosing schedules of ME-401, a selective phosphatidylinositol 3-kinase ("PI3K") delta inhibitor, to optimize the clinical risk-benefit ratio in patients with relapsed/refractory follicular lymphoma. The data announced today continue to support the rationale for MEI's planned Phase 2 study that evaluates both a continuous (CS) and intermittent (IS) dosing schedule of ME-401 as a means to enhance the drug candidate's clinical profile and thus potentially deliver improved benefits to patients. The Phase 2 study is expected to start around year-end and is intended to support MEI's accelerated approval registration strategy if successful.
- PR Newswire
MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting
SAN DIEGO, Dec. 1, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data presented at the 2018 American Society of Hematology (ASH) annual meeting demonstrating that voruciclib, MEI's orally available CDK9 inhibitor, synergistically induced apoptosis at clinically relevant concentrations when combined with venetoclax (marketed as Venclexta®) in human derived acute myeloid leukemia (AML) cells lines and patient samples. Voruciclib is currently being evaluated in a Phase 1b dose ranging study in patients with B-cell malignancies.
- Simply Wall St.
Is MEI Pharma Inc’s (NASDAQ:MEIP) CEO Paid At A Competitive Rate?
Dan Gold became the CEO of MEI Pharma Inc (NASDAQ:MEIP) in 2010. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
- GlobeNewswire
Market Trends Toward New Normal in Lightbridge, MEI Pharma, Good Times Restaurants, Lilis Energy, Microbot Medical, and S&W Seed — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
